Patents by Inventor Huijin FENG

Huijin FENG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF
    Publication number: 20230167129
    Abstract: The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.
    Type: Application
    Filed: October 8, 2022
    Publication date: June 1, 2023
    Inventors: Bing Zhou, Wei Tang, Xiangbo Yang, Huimin Lu, Mengying Gao, Yaxi Yang, Huijin Feng
  • Heterocyclic amide for inhibiting RIP1 kinase and uses thereof
    Patent number: 11498927
    Abstract: The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: November 15, 2022
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Bing Zhou, Wei Tang, Xiangbo Yang, Huimin Lu, Mengying Gao, Yaxi Yang, Huijin Feng
  • HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF
    Publication number: 20210371430
    Abstract: The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.
    Type: Application
    Filed: October 8, 2019
    Publication date: December 2, 2021
    Inventors: Bing ZHOU, Wei TANG, Xiangbo YANG, Huimin LU, Mengying GAO, Yaxi YANG, Huijin FENG